Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 13.8% – What’s Next?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares traded up 13.8% during mid-day trading on Friday . The company traded as high as $2.48 and last traded at $2.48. 2,742,828 shares were traded during mid-day trading, an increase of 2% from the average session volume of 2,687,534 shares. The stock had previously closed at $2.18.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on TSHA shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Chardan Capital restated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Up 13.3 %

The company has a market capitalization of $506.20 million, a P/E ratio of 3.92 and a beta of 0.44. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a 50 day moving average of $1.97 and a 200-day moving average of $2.37.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently made changes to their positions in the business. Artal Group S.A. raised its holdings in shares of Taysha Gene Therapies by 0.7% during the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after acquiring an additional 24,444 shares in the last quarter. Geode Capital Management LLC increased its position in Taysha Gene Therapies by 23.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after purchasing an additional 682,273 shares during the period. State Street Corp increased its position in Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after purchasing an additional 150,647 shares during the period. Quantum Private Wealth LLC raised its holdings in Taysha Gene Therapies by 5.1% in the 3rd quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock worth $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter worth about $931,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.